Benjamin Edwards Inc’s GSK GSK Stock Holding History

Benjamin Edwards Inc’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$297K	Buy	5,670 +454	+9%	+$24K	﹤0.01%	1240
2026 Q1	$288K	Sell	5,216 -13,437	-72%	-$728K	﹤0.01%	1176
2025 Q4	$915K	Sell	18,653 -4,539	-20%	-$212K	0.01%	742
2025 Q3	$1M	Buy	23,192 +1,364	+6%	+$53.3K	0.01%	688
2025 Q2	$838K	Buy	+21,828	New	+$834K	0.01%	686
2023 Q3	–	Sell	-114	Closed	-$4K	–	656
2023 Q2	$4K	Hold	114	–	–	﹤0.01%	621
2023 Q1	$4K	Sell	114 -118	-51%	-$4.13K	﹤0.01%	637
2022 Q4	$8K	Hold	232	–	–	﹤0.01%	603
2022 Q3	$7K	Buy	232 +1	+0.4%	+$38	﹤0.01%	590
2022 Q2	$13K	Buy	231 +3	+1%	+$166	﹤0.01%	558
2022 Q1	$12K	Buy	+228	New	+$12.4K	﹤0.01%	594

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Benjamin Edwards Inc's GSK Position: Q2 2026 in Review

Benjamin Edwards Inc increased its GSK (GSK) stake by 8.7% in Q2 2026, buying an estimated $24K and bringing the position to 5,670 shares worth $297K. The position accounts for ﹤0.01% of the portfolio, ranked #1240.

Benjamin Edwards Inc first reported a position in GSK in Q1 2022 and has held it in 11 quarters since. The position peaked at $1M in Q3 2025. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Benjamin Edwards Inc held 5,670 shares of GSK worth $297K as of Q2 2026.
Benjamin Edwards Inc bought 454 GSK shares in Q2 2026, an estimated $24K.
GSK made up ﹤0.01% of Benjamin Edwards Inc's portfolio in Q2 2026, its #1240 holding.
Benjamin Edwards Inc first reported a position in GSK in Q1 2022 and has held it in 11 quarters since.
Benjamin Edwards Inc's GSK position peaked at $1M in Q3 2025.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Benjamin Edwards Inc's 13F filing for Q2 2026, filed 24 Jul 2026.